Home About us Services Contact
 

Traction Drives Interest

Traction Drives Interest

Overall, the firm’s commercial traction with Casgevy, combined with a growing pipeline and a projected lift in 2026 revenue, remains the central narrative driving investor interest, while the sizable quarterly and annual losses, reliance on Vertex, and the recent equity issuance temper expectations of short‑term profitability.
16/02/2026 | CRISPR Therapeutics AG